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Abstract: 
Introduction: 
The true burden of fungal infection in Pakistan is unknown. High risk populations for fungal 
infections (tuberculosis (TB), diabetes, chronic respiratory diseases, asthma, cancer, transplant 
and HIV infection) are numerous. Here we estimate the burden of fungal infections to highlight 
their public health significance.  
Methods: 
Whole and at risk population estimates were obtained from the WHO (TB), BREATHE study 
(COPD), UNAIDS (HIV), GLOBOCAN (cancer) and Heartfile (diabetes). Published data from 
Pakistan reporting fungal infections rates in general and specific populations was reviewed and 
used when applicable. Estimates were made in for the whole population, or specific populations 
at risk, as previously described in the LIFE methodology. 
Results: Of the 1,845,000,00 people in Pakistan, an estimated 3,280,549 (1.78%) people are 
affected by a serious fungal infection, omitting all cutaneous infection, oral candidiasis and 
allergic fungal sinusitis, which we could not estimate. Compared with other countries the rates of 
candidaemia (21/100,000) and mucormycosis (14/100,000) are estimated to be very high, and are 
based on data from India. Chronic pulmonary aspergillosis rates are estimated to be high 
(39/100,000) because of the high TB burden. Invasive aspergillosis was estimated to be around 
5.9/100000.  Fungal keratitis is also problematic in Pakistan with an estimated rate of 
44/100,000.  
Conclusions: Pakistan probably has a high rate of certain life or sight-threatening fungal 
infections.   
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Introduction:  
A tremendous burden of infectious diseases and non-communicable diseases (NCD) exists in 
Pakistan (1, 2). In the absence of national healthcare system, very limited surveillance is done 
with regards to various infectious and non-infectious diseases. Fungal infections are no 
exceptions and the true burden of even a single fungal infection is unknown. Fungal infections 
have been recently identified as “hidden killers” as mortality due to top ten invasive fungal 
infections (IFI) have been estimated to be equivalent to tuberculosis (TB) and now significantly 
exceed malaria (3). Laboratory and institutional based reports from the country highlight the 
existence of these infections in both community and nosocomial settings. High risk populations 
for fungal infections (TB, diabetes, chronic respiratory diseases, asthma, and cancer) are 
prevalent in Pakistan (4, 5, 6). The situation becomes more complicated with poor fungal 
diagnostic capabilities of most laboratories in Pakistan, emergence of antifungal resistance, lack 
of antimicrobial stewardship, poor infection control practices and non-availability of essential 
antifungal agents.  
In this study we have estimated burden of fungal infections in Pakistan to highlight the public 
health significance of these infections.  
Methods: 
The resources used for population estimates and morbidity data of conditions at risk were 
determined by reviewing national and global data (Table 1) (7-34).  Published data from Pakistan 
reporting fungal infections rates in general and specific populations was reviewed and used when 
applicable (Table 1).  Estimates were made in for the whole population, or specific populations 
at risk, as previously described in the LIFE methodology. 
Results and discussion:  
Based on our data analysis, in the 185 million people in Pakistan, an estimated 3.28 million 
people (1.78%) yearly are affected by a serious fungal infection (Table 2).  
Cryptococcal meningitis and Pneumocystis pneumonia: 
We estimated that yearly around 794 and 2,200 cases of cryptococcal meningitis and PCP occur 
in HIV infected patients respectively in Pakistan.  
Cryptococcal infections with variable clinical presentations have been reported in various 
immunocompromised patient populations from Pakistan (8, 9, 35). Two studies in HIV patients 
from Pakistan have reported a rate 2.5% and 9% of cryptococcal meningitis in their patients (8, 
9).  Another study assessing culture positive meningitis in cancer patients reported a rate of 1 in 
40,000 cancer patients (11).  
PCP in HIV patients from Pakistan has been reported to occur at a frequency of around 16% in 
two studies (8, 9). Apart from HIV populations its incidence in other patient populations has not 
been reported from Pakistan. A retrospective analysis of 30 cases of PCP from a tertiary care 
hospital has reported HIV infection as an underlying disorder in 30% of their patients (36). It 
would not be reasonable to extrapolate this ratio to the whole of Pakistan, because of the 
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selective nature of patients seen at this center. There is a general lack of studies estimating PCP 
incidence in these specific populations.  
Oesophageal candidiasis: 
The annual burden of oesophageal candidiasis is estimated to be around 3231 cases in HIV 
infected patients. Oesophageal candidiasis is an opportunistic infection in patients with deficient 
cell mediated immunity and is an AIDS-defining illness. Variable rates of oesophageal 
candidiasis ranging from 14-33% have been reported in HIV patients from Pakistan (8, 9, 12). 
This infection has also been reported in non-HIV patients in Pakistan with carcinoma, diabetes 
mellitus, chronic steroid use and broad spectrum antibiotics as significant risk factors (37). 
However, the true burden of oesophageal candidiasis could not be estimated in non-HIV patients. 
Candidemia: 
Based on data from India (14, 15), we estimated a high burden of candidemia in our population. 
Case fatality rate ranges from 23%-52% in reports from Karachi (38, 39) and 24% from a 
neonatal ICU (40). If a 40% mortality rate is used, then an estimated 15,498 people die with 
candidemia annually in Pakistan. Furthermore, candidemia is only a subset of all patients with 
invasive candidiasis, as blood cultures are only about 38% sensitive (41, 42). This situation 
becomes worse with increase in isolation of fluconazole resistant Candida species including 
Candida auris in the country (43).  
Patients with upper gastro-intestinal disease and prolonged ICU stay have higher proportion of 
intraabdominal candidiasis compared to lower gastro-intestinal surgery patients with short stay 
who have moderate risk (44). Extrapolating from the ICU admission rate of 1.6/100,000 into 
ICU beds reported from a regional country Sri Lanka (45), and assuming 50% of patients 
admitted to ICUs are for surgical reasons, the population at risk for intra-abdominal candidiasis 
is calculated to be 1480. Among surgical ICU patients, intra-abdominal candidiasis is about 10% 
in patients with moderate risk, which includes patients with upper gastrointestinal surgery. This 
brings the burden of intra-abdominal candidiasis to 148. However this may be an underestimate 
as there are limited ICU beds and a large undetermined number of patients may end up 
remaining in general wards without intensive care. 
Mucormycosis:  
Around 25,830 cases of mucormycosis were estimated from Pakistan using a prevalence of 
0.14/1,000 population and 38% mortality as computed in India (21). Recent data from 
developing countries indicate increasing trends in mucormycosis cases, including India (46). 
Several reports from Pakistan also indicate mucormycosis as an infection in various patient 
groups (47-49). High mortality rates despite aggressive surgical debridement and amphotericin B 
therapy have been reported; an attributable mortality rate of 38% leads to ~9,815 patients 
expiring annually due to mucormycosis in Pakistan. Although infections have been reported in 
patients with no apparent risk factors (49), isolated renal mucormycosis has not yet been reported 
from Pakistan. Even if these cases (around 8% of our estimate) are removed from our estimation, 
the burden of mucormycosis is still substantial. In addition, proportion of population highest at 
risk for mucormycosis, i.e. diabetics, is higher in Pakistan than in India: 10% (50) versus 8% of 
general population, respectively (51). 
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Recurrent vulvovaginal candidiasis: 
It is estimated that yearly 2,821,435 cases of recurrent vulvovaginal candidiasis occur in females 
of reproductive age group in Pakistan. Due to both over- and under-diagnosis and self-treatment 
with over the counter topical antifungal agents, population based data regarding the frequency of 
recurrent vulvovaginitis in Pakistan is lacking. Our estimates in this study were determined using 
data by Foxman et al that reports recurrent vulvovaginitis in ~9% of unselected females based on 
internet questionnaires (22, 52). We have used a 6% rate, as women are inclined to over-
diagnose ‘yeast’ infection. A study conducted to estimate the burden of reproductive tract 
infection in urban women in Pakistan reports vaginal candidiasis as the second most common 
genital infection with a prevalence of 7-12% (53).  
Aspergillosis: 
We estimated a high burden of ABPA and SAFS in adult asthmatic patients in Pakistan, because 
asthma is relatively common (3.3% prevalence adapted from India) (23) with 10% of these 
developing severe asthma. Annually around 94358 adult asthmatic patients will develop ABPA 
and 129,776 will develop SAFS. Although ABPA has been reported in asthmatic children, from 
India (54), and SAFS from the UK (55) we have not attempted to estimate the burden of these 
problems.  Aspergillus species has been reported to be most common environmental fungus from 
Southern Pakistan in both indoor and outdoor environment (56). Higher indoor concentration of 
Aspergillus species in the indoor environment was also associated with acute asthma 
exacerbation (57). ABPA, often misdiagnosed as TB, has been reported to occur in patients from 
Pakistan (58). In one series around 76% of ABPA cases occurred in asthmatic patients followed 
by 17% cases in patients with cystic fibrosis or non-cystic fibrosis bronchiectasis (59).  
ABPA is known to occur in older children, teenagers and adults with cystic fibrosis. Cystic 
fibrosis is often underdiagnosed in the Pakistani population as appropriate diagnostic tools are 
not available; therefore accurate prevalence in the country is not known (60). However, CF 
prevalence of 1 in 9,000 population has been reported in South Asian Canadian immigrants as 
well as WHO estimates suggest a prevalence of 1 in 10,000-40,000 in Asian population (25, 61). 
Considering a prevalence of 1 in 10,000 population and as 9% of these will develop ABPA as 
suggested by a recent meta-analysis, we have estimated 1,661 cases per year in Pakistan (26).   
Chronic pulmonary aspergillosis (CPA) prevalence is also estimated to be high (39/100,000) 
because of the high TB burden, with only few cases not related to TB (i.e. due to sarcoidosis). 
CPA occurs in immunocompetent individuals with prior or existing pulmonary cavitary or non-
cavitary disease (62, 63). Patients with prior pulmonary TB, sarcoidosis, ABPA, COPD and 
pneumothorax are particularly at risk of developing CPA. As seen in other high TB burden 
countries a high burden of CPA has been estimated in Pakistan. In Pakistan it is extremely 
difficult to diagnose CPA as tests to detect Aspergillus-specific IgG and IgE, crucial for 
diagnosis of CPA and ABPA are not available in many centers. Non-availability of these tests 
makes it problematic to exclude CPA in smear negative patients with suspected TB.  
Invasive aspergillosis (IA) is mainly reported in immunocompromised individuals; however in 
developing countries including Pakistan IA has been reported in host with no apparent immune 
defect (64). Around 10,172 COPD patients develop invasive aspergillosis annually in Pakistan 
(using the 3.9% rate in hospitalized patients from China, based on culture and imaging) (17). 
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Assuming that 2% of all cancers as reported in Karachi, Pakistan are myeloid leukemia (19) and 
in these patients 10% will develop IPA (20) we estimated around 296 cases in this population. 
This is probably an underestimate as other patients with hematological malignancies are also at 
risk of IPA, therefore an equal number of cases was estimated for all other hematological 
conditions. In addition, we also estimated 177 cases of IPA per year in lung cancer patients. 
Emerging populations at risk of IPA are patients with preexisting lung disease like COPD, 
critically ill patients in ICU, especially those given corticosteroids, diabetes and advanced liver 
disease (64). Invasive aspergillosis has been reported from Pakistan in patients with bone 
marrow, renal and liver transplant and hematological malignancy (65-67). A study conducted 
recently at our center on 69 patients revealed diabetes and chronic renal failure as most 
prominent risk factors for pulmonary aspergillosis. Prior or active TB was found in 50% of these 
patients. The overall mortality was 20% with around 70% mortality in patients admitted to ICU. 
Diabetes mellitus was identified as an independent risk factor for mortality (68).  
Fungal keratitis:  
Various studies from the country report rates of fungal keratitis ranging from 8-51% amongst 
patients presenting with infectious keratitis (31-33). Based on data from China (30) around 
273,060 cases of microbial keratitis annually are estimated in Pakistan. A fungal etiology is 
likely in 80,553 cases. Our estimated rates of fungal keratitis in Pakistan (table 2) are 
approaching those of Nepal where fungal keratitis has been reported to be a common fungal 
infection with a rate of 73/100,000 (69).  This rate is alarming and points toward a major need 
for improved diagnostics, enhanced management strategies and education. 
Mycetoma: 
Using an incidence of 0.01-0.1/100,000 (34), around 92 cases of mycetoma occur annually in 
Pakistan. Around 40% of cases are fungal with Madurella mycetomatis as the most common 
agent (34).  Apart from sporadic case reports that confirm the existence of disease in the country, 
no data regarding burden of mycetoma is available from Pakistan. A study performed in Pakistan 
has reported that around 40% (5/12) of all cases of mycetoma in their center were due to fungi 
(70). Due to the paucity of exact data a burden of only 18-185 cases per year seems an 
underestimate. 
Conclusion: 
Fungal infections are common in Pakistan, but grossly under-diagnosed. Diseases of real concern 
are candidaemia (21/100,000) and invasive candidiasis, mucormycosis (14/100,000), which may 
exceed invasive aspergillosis, fungal keratitis (44/100,000) and fungal asthma (>100/100,000). 
Efforts to improve diagnosis of these conditions, better understand their local epidemiology, and 
institute preventative measures are called for.  
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Table 1: Baseline population and prevalence of fungal infections  
Disease Baseline Population  Assumption Prevalence  Ref 
Cryptococcal 
meningitis 
HIV patients below CD4 cell 
count of 200 cells/uL  
 
Estimate: HIV patients in need 
of ART: 55,000  
 
 
All Cancer patients 
Estimate: 14,8041 
Number eligible for 
ARV divided by 2 to 
get the rough number 
<200 and then 
assuming that only 
50% present for care in 
that year 
2.5-9%  
 
 
 
 
0.0025% 
7, 8, 9 
 
 
 
 
 
 
 
10, 11 
Pneumocystis 
pneumonia 
HIV patients below CD4 cell 
count of 200 cells/uL 
 
Estimate: 
HIV patients in need of ART: 
55,000 
Number eligible for 
ARV divided by 2 to 
get the rough number 
<200 and then 
assuming that only 
50% present for care in 
that year 
16% 7, 8, 9 
 
Oesophageal 
candidiasis 
HIV patients below CD4 cell 
count of 200 cells/uL 
 
Estimate: 
HIV patients in need of ART: 
55,000 
Number eligible for 
ARV divided by 2 to 
get the rough number 
<200 and then 
assuming that only 
50% present for care in 
that year 
14-33% 7, 8, 9 
12 
 
Candidemia General population  
 
Estimate: 184,500,000 
 
 
 
21/100,000 13, 14, 
15 
Invasive aspergillosis Chronic obstructive pulmonary 
disease 
 
Estimate: 
Adults >40 y in Pakistan (20.4% 
of population) = 37,638,000  
 
 
Estimate: 
COPD prevalence (2.1% of adults 
>40y) =790,398 
33% get hospitalised =260,831 
admissions 
33% of COPD >40 
years of age are 
admitted to hospital 
each year and  
3.9% will develop IPA 
 
 
 
 
 
 
 
 
 
3.9% 
 
 
 
 
 
 
 
 
 
 
 
 
 
13, 16, 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
 
Lung cancer patients 
Estimate: 6,800 
 
Myeloid leukemia (2% of all 
cancers) 
Estimate: 2,961 
 
2.6%  
 
10% rate of IA in 
AML (over the year, 
not per neutropenic 
episode) + equal 
number for all other 
haematological 
conditions 
 
2.6% 
 
 
 
10% 
 
10, 18 
 
 
 
19, 20 
Mucormycosis General population 
 
Estimate: 184,500,000 
 14/100,000 13, 21 
Recurrent vaginal 
candidiasis  
(4x/year +) 
Adult female between age 15-50 
years (50.6% of female 
population) 
 
Estimate:  47,023,921 
 6% 13, 22 
Allergic 
Bronchopulmonary 
Aspergillosis 
Adult asthmatic patients [61% 
of population are adults and of 
those 3.3% are asthmatic] 
 
Estimate: 3707897 
 
Cystic Fibrosis 
 
Estimate: 18,450 
2.5 of adult asthmatic 
patients in Pakistan 
will develop ABPA 
2.5%  
 
 
 
 
 
 
 
9% 
13, 23, 
24 
 
 
 
 
 
 
13, 25, 
26 
Severe asthma with 
fungal sensitization 
Adult patients with severe 
asthma (10% of adult asthmatic) 
 
Estimate: 370790 
 
35% of adult asthmatic 
will develop SAFS 
35%  13, 23, 
24 
 
 14 
Chronic pulmonary 
aspergillosis 
Pulmonary TB alive patients in 
2014 (estimated by subtracting 
extrapulmonary cases and expired 
cases from total new cases)  
Estimate (2014): [308,417-
(57,463+48,100)]=202,854 
Alive pulmonary TB patients 
with cavitary disease  
 
Estimate: 70,999 
 
Pulmonary TB alive patients 
with non-cavitary disease 
 
Estimate: 131,855 
 
 
 
Sarcoidosis 
 
Estimate: 8,432 
35% (25-50%) of alive 
cases Pulmonary TB in 
2014 will develop 
cavitary disease; of 
these 22% will develop 
CPA 
 
 
 
 
 
65% (50%-75%) of 
alive cases Pulmonary 
TB in 2014 will 
develop non-cavitary 
disease; of these 2% 
will develop CPA 
 
Incidence of 
sarcoidosis is 
4.57/100000 
population; of these 
6% will develop CPA 
22%  
 
 
 
 
 
 
 
 
 
 
2% 
 
 
 
 
 
 
6% 
5, 27 
 
 
 
 
 
 
 
 
 
 
27 
 
 
 
 
 
 
 
13, 28, 
29 
 
 
 
Fungal keratitis Patients with Infectious 
keratitis (0.148% of general 
population) 
 
Estimate: 273,060 
 
 8%-51% 13,  
30- 33 
Mycetoma General population 
 
Estimate: 184,500,000 
 
 0.01-
0.1/100000 
13, 34 
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Table 2: Estimated of burden of fungal infections 
 
*Mean incidence  
§ In patients with cystic fibrosis 
# In patients with sarcoidosis 
& rate for female population only 
 Total 
burden 
Number of infections per underlying disorder per year Rate/100K  
 None HIV/AIDS Respiratory Cancer/Tx ICU 
Cryptococcal 
meningitis 
794 - 790* (344-
1,237) 
- 4 - 0.4  
Pneumocystis 
pneumonia 
2,200 - 2,200 - - - 1.2 
Oesophageal 
candidiasis 
3,231*  - 3,231 
(1,925-
4,537) 
- - -  1.7  
Candidemia 38,745 - - - - - 21 
Intra-
abdominal 
candidiasis 
148     148 0.08 
Invasive 
aspergillosis 
10,949 - - - 777 10,172 5.9 
Mucormycosis 25,830 - - - - - 14 
Recurrent 
vaginal 
candidiasis 
(4x/year) 
2,821,435 2,821,435 - - - - 1529& 
ABPA 94,358  - - 92,697 + 
1,661§  
- - 51 
SAFS 129,776 - - 129776   70 
Chronic 
pulmonary 
aspergillosis 
72,438  - - 71,932+506# - - 39  
Fungal 
keratitis 
80,553*  80,553* 
(21,845-
139,260) 
- - - - 44  
Mycetoma 92*  92* (18-
185) 
- - - - 0.05  
Total burden 
estimated 
3,280,549      1,778 
